Management of symptomatic toxicity from EGFR inhibitor therapy (monoclonal antibodies and TKIs) pathway

Management of symptomatic toxicity from EGFR inhibitor therapy (monoclonal antibodies and TKIs) pathway

STARTFINISHCreated with SnapWhat grade?STARTFINISHCreated with SnapGrade 1<10% body surfacearea (BSA) affectedwith/without symtomse.g. pruritis, burning,tightness.STARTFINISHCreated with Snap- Continue EGFRi- Review skin careadvice (see info)STARTFINISH- Continue topicaltherapy untilresolution of rash- Review in 2 weeks- Either patient self...STARTFINISHCreated with SnapGrade 2-10-30% BSA affecetdwith or withoutsymptoms e.g.pruritis, burning,tightness....STARTFINISHCreated with Snap- Continue EGFRi- CheckFBC/U&Es/LFTs- Review skin careadvice (see info)STARTFINISH- Continue topicaltherapy untilimprovement.- Review in 2 weeks.(see info for more)STARTFINISHCreated with SnapGrade 3>30% BSA affectedwith/withoutsymptoms e.g.pruritis, burning,tightness....STARTFINISHCreated with SnapSee info formanagementSTARTFINISHSee info for follow upSTARTFINISHCreated with SnapGrade 4- Any % BSA affectedwith/withoutsymptoms e.g.pruritis, burning,tightness......